+357 96 030922
info@marketpublishers.com

US Skin Cancer Drug Pipeline Analysis

https://marketpublishers.com/r/UF9699D907DEN.html
Date: January 2014
Pages: 310
Price: US$ 1,200.00 (Single User License)
ID: UF9699D907DEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

The market for skin cancer in the US is expected to grow significantly owing to reasons like increasing number of patients and entry of new therapies which are in the pipeline. Additionally, the organic growth of key marketed drugs is also another major factor driving the growth in the US market. Of the different types of skin cancers in the US, Melanoma is the most common. Though this segment accounts for just 5% of the overall US skin cancer market, it is a major factor causing 75% deaths in the region. Also, the US market witnesses a greater use of adjuvant therapy to treat early stage melanoma, as compared to the other regions.

With surgery being along with early detection is by far the most successful method of treating skin cancer in the US, the risk of recurrence in the patients is high. Additionally, the survival rates for the patients with advanced stages of the disease are very low. This has been a major challenge in the US market and companies investing in this space have been continuously researching on various options to improve the survival rates.

“US Skin Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of skin cancer in US. Research report covers all drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the US skin cancer drug market based upon development process.

Following parameters for each drug profile in development phase are covered in “US Skin Cancer Drug Pipeline Analysis” research report:

Drug Profile Overview

+357 96 030922
info@marketpublishers.com

Alternate Names for Drug

Active Indication

Phase of Development

Mechanism of Action

Brand Name

Patent Information

Orphan Designation by Indication, Country & Organisation

Country for Clinical Trial

Owner / Originator/ Licensee/Collaborator

Administrative Route

Drug Class

ATC Codes

Number of Skin Cancer Drug in Pipeline by Clinical Phase:

Research: 3

Preclinical: 29

Clinical: 5

Phase 0: 1

Phase-I: 29

Phase-I/II: 18

+357 96 030922
info@marketpublishers.com

Phase-II: 41

Phase-III: 13

Registered: 4

Marketed: 18

Unknown: 1

+357 96 030922
info@marketpublishers.com

Contents

+357 96 030922
info@marketpublishers.com

EACH DRUG PROFILE HAS TABLES REPRESENTING FOLLOWING INFORMATION:

- Alternate Names
- Originator & Owner
- Collaborator
- Technology Provider
- Licensee
- Highest Development Phase
- Indications
- Class

+357 96 030922
info@marketpublishers.com

Mechanism of Action

ATC code

Designated Brand Name & Orphan Designation

+357 96 030922
info@marketpublishers.com

About

The market for skin cancer in the US is expected to grow significantly owing to reasons like increasing number of patients and entry of new therapies which are in the pipeline. Additionally, the organic growth of key marketed drugs is also another major factor driving the growth in the US market. Of the different types of skin cancers in the US, Melanoma is the most common. Though this segment accounts for just 5% of the overall US skin cancer market, it is a major factor causing xx% deaths in the region. Also, the US market witnesses a greater use of adjuvant therapy to treat early stage melanoma, as compared to the other regions.

With surgery being along with early detection is by far the most successful method of treating skin cancer in the US, the risk of recurrence in the patients is high. Additionally, the survival rates for the patients with advanced stages of the disease are very low. This has been a major challenge in the US market and companies investing in this space have been continuously researching on various options to improve the survival rates.

In 2010, the total incidence of skin cancer in the US was estimated to be close to xx million, which is expected to increase to xx million by 2017. Additionally, on the global front, a decrease of xx in the stratospheric ozone is also likely to lead to xx additional cases of non-melanoma skin cancers and xx melanoma cases annually. Though the early diagnosis and treatment of skin cancer increase the survival rates significantly, the major challenge is that the drugs currently available in the market are highly toxic in nature. This has led to low response rates among patients.

Additionally, there are no specific drugs approved by the FDA for melanoma for the past decade. Thus, currently the patients of skin cancer are treated with chemotherapy (dacarbazine) and IL-2 (Proleukin). Both of these treatments have not shown any significant improvement in the overall survival rates, which has led to a high degree of unmet need among the patients.

It is most likely that in the future, the new launches of drugs specially for melanoma treatment would lead to more affordable and accessible options for the patients. Some of the drugs in the pipeline have the potential to be blockbusters for targeted therapies. By 2017, close to 10 new drugs are likely to be launched, with a few major drugs losing out on their patents in this period. With the expected entry of biosimilars/generics which would be of lower costs, the growth in the market is likely to

+357 96 030922
info@marketpublishers.com

be restrained. However, an increase in the adoption rates and more accessibility at lower prices is likely to be observed with the entry of generics into the market.

In the future, the pharma and biotech companies would require to invest significantly in developing novel medications which would lead to improvement in survival rates for metastatic melanoma and less toxicity. These new cancer therapies would demand premium pricing which would inturn result in higher revenue for the drug makers.

However, since the patients do not have sufficient options for reimbursements, they would tend to opt for biosimilars instead of expensive novel therapies. In order to overcome this, the pharmaceuticals and biotech companies would be required to offer more personalized therapies with the objective of providing the appropriate drug at the right dose for each patient. Technologies like genomic and proteomic data profiling are expected to provide novel molecular markers which would enable the process of detecting skin cancer progression. This is expected to generate significant opportunities for developing more effective therapies for skin cancer.

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: US Skin Cancer Drug Pipeline Analysis

Product link: https://marketpublishers.com/r/UF9699D907DEN.html

Price: US$ 1,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/UF9699D907DEN.html